# Doxorubicin With Cisplatin, High-Dose Methotrexate, and Additional Risk-Adapted Outpatient Chemotherapy

> **NCT00673179** · NA · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 7 (actual)

## Conditions studied

- Osteosarcoma

## Interventions

- **DRUG:** Doxorubicin
- **DRUG:** Cisplatin
- **DRUG:** Methotrexate
- **DRUG:** Leucovorin
- **DRUG:** Dexrazoxane
- **DRUG:** Ifosfamide
- **BEHAVIORAL:** Questionnaire
- **DRUG:** Gemcitabine
- **DRUG:** Sargramostim
- **PROCEDURE:** Surgery
- **DRUG:** Mesna

## Key facts

- **NCT ID:** NCT00673179
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-05
- **Primary completion:** 2010-11
- **Final completion:** 2010-11
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Low accrual.
- **Last updated:** 2014-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00673179

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00673179, "Doxorubicin With Cisplatin, High-Dose Methotrexate, and Additional Risk-Adapted Outpatient Chemotherapy". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT00673179. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*